Exact Mass: 211.1127698

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D006213 - Hallucinogens

Isoproterenol

4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol

Isoproterenol is only found in individuals that have used or taken this drug. It is an isopropyl analog of epinephrine; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. [PubChem]The pharmacologic effects of isoproterenol are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CB - Non-selective beta-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AB - Non-selective beta-adrenoreceptor agonists C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents

Orciprenaline

5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,3-diol

Orciprenaline is only found in individuals that have used or taken this drug. It is a beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]Orciprenaline is a moderately selective beta(2)-adrenergic agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of orciprenaline are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CB - Non-selective beta-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AB - Non-selective beta-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents

Methoxamine

Glaxo wellcome brand 1 OF methoxamine hydrochloride

Methoxamine is only found in individuals that have used or taken this drug. It is an alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system. [PubChem]Methoxamine acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic and diastolic). C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents KEIO_ID M169; [MS2] KO009056 KEIO_ID M169

3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole

1,4-Dimethyl-5H-pyrido[4,3-b]indol-3-amine, 9ci

3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole is a powerful mutacarcinogen found in cooked food D009676 - Noxae > D009153 - Mutagens

Pramipexole

6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate

Pramipexole is a medication indicated for treating Parkinsons disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in bipolar disorder. Pramipexole is classified as a non-ergoline dopamine agonist. D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D020011 - Protective Agents > D000975 - Antioxidants Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

Varenicline

(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0²,¹¹.0⁴,⁹]hexadeca-2,4,6,8,10-pentaene

Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BA - Drugs used in nicotine dependence C78272 - Agent Affecting Nervous System > C47796 - Cholinergic Agonist > C73579 - Nicotinic Agonist D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018679 - Cholinergic Agonists S - Sensory organs > S01 - Ophthalmologicals D000077444 - Smoking Cessation Agents Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].

Dexpramipexole

6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate

http://casmi-contest.org/challenges-cat1-2.shtml; CASMI2012 LC Challenge 17

1,3-Diphenylguanidine

CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2907; ORIGINAL_PRECURSOR_SCAN_NO 2905 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2905; ORIGINAL_PRECURSOR_SCAN_NO 2903 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2885; ORIGINAL_PRECURSOR_SCAN_NO 2881 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2873; ORIGINAL_PRECURSOR_SCAN_NO 2871 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2951; ORIGINAL_PRECURSOR_SCAN_NO 2949 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2908; ORIGINAL_PRECURSOR_SCAN_NO 2904 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6081; ORIGINAL_PRECURSOR_SCAN_NO 6079 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6105; ORIGINAL_PRECURSOR_SCAN_NO 6104 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6127; ORIGINAL_PRECURSOR_SCAN_NO 6125 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6137; ORIGINAL_PRECURSOR_SCAN_NO 6136 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6136; ORIGINAL_PRECURSOR_SCAN_NO 6134 CONFIDENCE standard compound; INTERNAL_ID 845; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6135; ORIGINAL_PRECURSOR_SCAN_NO 6134 CONFIDENCE standard compound; INTERNAL_ID 2487 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1007

methyl 2,2-dimethyl-3-[3-(hydroxyimino)-2-methyl-1-propenyl)-cyclopropanecarboxylate

7beta-Acetoxy-1-methoxymethyl-1,2-dehydro-8alpha-pyrrolizidin

Normacromerine

N-Methyl-3-hydroxy-4,5-dimethoxyphenethylamine

Tetrahydrocantleyine

C8H13N5O2 (211.10691980000001)

Viocidic acid

2-Amino-3-ethyl-9H-pyrido(2,3-b)indole

Varenicline

(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaene

N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BA - Drugs used in nicotine dependence C78272 - Agent Affecting Nervous System > C47796 - Cholinergic Agonist > C73579 - Nicotinic Agonist D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018679 - Cholinergic Agonists S - Sensory organs > S01 - Ophthalmologicals D000077444 - Smoking Cessation Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3636 Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].

methoxamine

C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents

Pramipexole

(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D020011 - Protective Agents > D000975 - Antioxidants Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

mescaline

A phenethylamine alkaloid that is phenethylamine substituted at positions 3, 4 and 5 by methoxy groups. D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D006213 - Hallucinogens

Isoprenaline

isoproterenol

4-(azepan-1-ylmethyl)-1,3-thiazol-2-amine

dioxethedrin

C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent

1-(4-Aminophenoxy)-3-ethoxy-2-propanol

5,5-dimethyl-3-oxocyclohex-1-enyl dimethylcarbamate

tert-butyl 5-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate

C8H13N5O2 (211.10691980000001)

(4-AMINO-FURAZAN-3-YL)-(4-METHYL-PIPERAZIN-1-YL)-METHANONE

1-(3-Isopropylphenyl)cyclopropanamine hydrochloride (1:1)

(R)-Cyclopropyl(2,4-dimethylphenyl)Methanamine hydrochloride

1-phenylcyclohexan-1-amine,hydrochloride

3-(DIFLUOROMETHYLENE)-1,1,2,2-TETRAFLUOROCYCLOPROPANE

C11H17NOS (211.1030792)

tert-butyl 2-oxo-7-azabicyclo[2.2.1]heptane-7-carboxylate

(R)-cyclopentyl(phenyl)methanamine,hydrochloride

Mefenorex

A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29728 - Anorexiant

4-(2,4-Difluorobenzyl)piperidine

C12H15F2N (211.1172494)

Dexpramipexole

D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D020011 - Protective Agents > D000975 - Antioxidants

4-Phenylazepane

2,3-Dimethoxy-6-(trimethylsilyl)pyridine

2,3-Dimethoxy-5-(trimethylsilyl)pyridine

1-(cyclobutanecarbonyl)piperidine-3-carboxylic acid

Levisoprenaline

C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

2,2-[(3-Methoxyphenyl)imino]diethanol

(S)-Cyclopropyl(2,4-dimethylphenyl)Methanamine hydrochloride

4-(O-TOLYL)PIPERIDINE HYDROCHLORIDE

(ar-vinylbenzyl)trimethylammonium chloride

1-Cyclohexyl-5-Oxo-Pyrrolidine-3-Carboxylic Acid

C8H13N5O2 (211.10691980000001)

2-Amino-4-isopropoxy-6-(methylamino)-5-nitroso-pyrimidine

N-methyl-4-phenyldiazenylaniline

5,7-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine,hydrochloride

tert-butyl 3-ethynylmorpholine-4-carboxylate

2-Benzylpiperidine hydrochloride

5-(diethylaminomethyl)-2-methylfuran-3-carboxylic acid

1-cyclopentyl-6-oxopiperidine-3-carboxylic acid

N-{[Dimethoxy(methyl)silyl]methyl}aniline

1-(2-HYDROXYETHYL)-4-METHANESULFONYLPIPERAZINE

TERT-BUTYL 2-OXA-3-AZABICYCLO[2.2.2]OCT-5-ENE-3-CARBOXYLATE

N-CYCLOHEXYLANILINE HYDROCHLORIDE

1-Benzyl-4,4-difluoropiperidine

C12H15F2N (211.1172494)

tert-Butyl(1R,4S)-2-oxo-7-azabicyclo[2.2.1]heptane-7-carboxylate

Benzenemethanamine, 3,4,5-trimethoxy-a-methyl-,(S)-

N-(2,3-DIMETHYLBENZYL)CYCLOPROPANAMINE HYDROCHLORIDE

4-(3-Methoxypropoxy)-2,3-dimethylpyridine-N-oxide

3-cyclohexyl-4-ethyl-1H-1,2,4-triazole-5-thione

4-METHYL-4-PHENYLPIPERIDINE HYDROCHLORIDE

4-[[bis-(2-Hydroxyethyl)amino]methyl]phenol

Benzenemethanamine, 2,3,4-trimethoxy-a-methyl-,(S)-

1-Propanol,2-amino-2-methyl-,benzoate

Ethyl 3-oxooctahydro-1H-cyclopenta[c]pyridine-4-carboxylate

tert-butyl 6-oxo-3-aza-bicyclo[3.2.0]heptane-3-carboxylate

N-METHYL-3,4,5-TRIMETHOXYBENZYLAMINE

METHYL 4-CARBAMOYLBICYCLO[2.2.2]OCTANE-1-CARBOXYLATE

Methyl 5-[(diethylamino)methyl]-2-furoate

2-(Cyclopropylcarbamoyl)cyclohexanecarboxylic acid

(S)-2-(3,5-DIMETHYLPHENYL)PYRROLIDINE HYDROCHLORIDE

4-(2-oxopyrrolidin-1-yl)cyclohexane-1-carboxylic acid

N,N,N-trimethyl-1-(4-vinylphenyl)methanaminium chloride

Triethanolamineborate

C6H18BNO6 (211.1227118)

2-phenylazepane (HCl)

C10H14FN3O (211.11208459999997)

4-(5-Fluoro-pyriMidin-2-ylaMino)-cyclohexanol

(R)-N-methyl-N-phenyl tert-butane-sulfinamide

C11H17NOS (211.1030792)

cis-7-Oxo-2-aza-bicyclo[3.2.0]heptane-2-carboxylic acid tert-butyl ester

tert-Butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate

TERT-BUTYL 5-OXO-2-AZASPIRO[3.3]HEPTANE-2-CARBOXYLATE

[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methanol

DIETHYLAMINE SALICYLATE

4-METHYL-2-PROPOXYANILINE HYDROCHLORIDE

3-(3-METHYLPHENYL) PIPERIDINE HYDROCHLORIDE

4-(3-METHYLPHENYL) PIPERIDINE HYDROCHLORIDE

4-(4-methylphenyl)piperidine,hydrochloride

2-(3,4-Difluorophenyl)azepane

C12H15F2N (211.1172494)

DL-BETA-(3,4-DIMETHOXYPHENYL)ALANINOL

1-(3-(TRIFLUOROMETHYL)PHENETHYL)HYDRAZINE

m-PEG2-O-Ph-NH2

(+)-Isoproterenol

(S)-orciprenaline

TMPEA

4-13-00-02919 (Beilstein Handbook Reference)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D006213 - Hallucinogens

2,6-Dihydroxypseudooxynicotinium(1+)

C10H15N2O3+ (211.108262)

L-prolyl-L-proline dipeptide

C10H15N2O3- (211.108262)

(2S,3R,4R)-1-(4-aminophenyl)pentane-2,3,4-triol

(R)-orciprenaline

3,6-Diaminoacridine(2+)

C13H13N3+2 (211.1109418)

5-Amino-2-methoxyphenol, TMS derivative

1-Methyl-4-phenylpyrrolidine-3,3-dicarbonitrile

isoproterenol

DL-Isoproterenol

R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CB - Non-selective beta-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AB - Non-selective beta-adrenoreceptor agonists C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents

orciprenaline

metaproterenol